The Food and Drug Administration (FDA) has just approved long -term injection to prevent HIV

US food The drug administration has just agreed to Lenacapavir, a form of injection from Human immunotherapy virus Prevention is approximately 100 percent effective and requires only two doses per year. sciences The magazine described medicine The most important scientific progress From 2024.

In clinical trials, Lenacapavir has proven to be 99.9 percent effective in preventing HIV through sexual transmission in people with a weight of more than 35 kilograms. The drug, which is anti -virus, works, not by stimulating the immune response, but by preventing HIV from multiplying during its early stages – specifically, by disrupting the virus’s capsule protein function. This happens as long as the body receives the injection every six months.

Lenacapavir has already been approved in some countries as a HIV treatment in people who have other treatments. However, before this week, its preventive use has not been approved anywhere, making the decision of the Food and Drug Administration a new development in the fight against HIV/AIDS.

The drug is not the first drug that can be taken proactively to protect against HIV: Prevention pills (Prep) was already available in many countries, including the United States. But this should be taken every day, ensuring constant access to these medications, and that people really remember to take them, It is a well -known challenge. It is hoped that the long -term effects of lanacabavir make it easy for people to stay protected against the virus.

According to her creator, Gilead Sciences, Lenacapavir will be marketed under the YEZTOGO brand name. The company adhered to manufacture 10 million doses by 2026.

“This is a historic day in the battle that has lasted for decades,” said Daniel Odai, President and CEO of Gilead. statement Wednesday.

However, the price of Lenacapavir may be an obstacle to access. YEZTOGO will have an annual list price of $ 28,218 per person in the United States. Winnie Bianima, CEO of the Joint United Nations Program on HIV/AIDS (show diseases), also has A mark has been placed in the past The drug cannot be tolerated for many people in Africa, where medicine has the ability to affect the greatest effect. Almost two thirds One of the people who live with HIV around the world live in sub -Saharan Africa.

Gillid said in a Last year’s statement It was “developing a strategy to enable broad and sustainable access worldwide” to Lenacapavir, although the company has not yet provided detailed information on how to do so. One of the options can be the “volunteer license”, as other companies are granted permission to produce and sell public versions of a patented product exclusively for people in some low -income countries (often low -income). Researchers at the University of Liverpool in the United Kingdom I have an account The value of LenacAPavir can be saved for a year for up to $ 25.

This story was originally appeared on Wireless En español It was translated from Spanish.